HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin

International Journal of Cardiology

Volumn 228, Issue , 2017, Pages 709-716

  Faxén, Ulrika Ljung ^a,b   Hage, Camilla ^a,b   Andreasson, Anna ^b,c   Donal, Erwan ^d   Daubert, Jean Claude ^d   Linde, Cecilia ^a,b   Brismar, Kerstin ^a,b   Lund, Lars H ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Adipocytokines; Adiponectin; Biomarker; Heart failure; Heart failure with preserved ejection fraction; Leptin

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; LEPTIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; CASE CONTROL STUDY; COMPLICATION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY;

ADIPONECTIN; AGED; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; LEPTIN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHENOTYPE; STROKE VOLUME;

EID: 84996598813     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.194     Document Type: Article

References (39)

1. [1] Butler, J., Fonarow, G.C., Zile, M.R., Lam, C.S., Roessig, L., Schelbert, E.B., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2:2 (2014), 97–112.
2. [2] Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62:4 (2013), 263–271.
3. [3] Kenchaiah, S., Evans, J.C., Levy, D., Wilson, P.W., Benjamin, E.J., Larson, M.G., et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347:5 (2002), 305–313.
4. [4] Oreopoulos, A., Padwal, R., Kalantar-Zadeh, K., Fonarow, G.C., Norris, C.M., McAlister, F.A., Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J. 156:1 (2008), 13–22.
5. [5] Haass, M., Kitzman, D.W., Anand, I.S., Miller, A., Zile, M.R., Massie, B.M., et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ. Heart Fail. 4:3 (2011), 324–331.
6. [6] Ghantous, C.M., Azrak, Z., Hanache, S., Abou-Kheir, W., Zeidan, A., Differential role of leptin and adiponectin in cardiovascular system. Int. J. Endocrinol., 2015, 2015, 534320.
7. [7] Beltowski, J., Adiponectin and resistin–new hormones of white adipose tissue. Med. Sci. Monit. 9:2 (2003), RA55–RA61.
8. [8] Lund, L.H., Freda, P., Williams, J.J., LaManca, J.J., LeJemtel, T.H., Mancini, D.M., Leptin resistance after heart transplantation. Eur. J. Heart Fail. 12:5 (2010), 516–520.
9. [9] Wannamethee, S.G., Shaper, A.G., Whincup, P.H., Lennon, L., Papacosta, O., Sattar, N., The obesity paradox in men with coronary heart disease and heart failure: the role of muscle mass and leptin. Int. J. Cardiol. 171:1 (2014), 49–55.
10. [10] Szabo, T., Scherbakov, N., Sandek, A., Kung, T., von Haehling, S., Lainscak, M., et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr. Metab. Cardiovasc. Dis. 24:1 (2014), 50–56.
11. [11] Donal, E., Lund, L.H., Linde, C., Edner, M., Lafitte, S., Persson, H., et al. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 11:2 (2009), 198–204.
12. [12] Unden, A.L., Elofsson, S., Brismar, K., Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin. Endocrinol. 63:1 (2005), 94–102.
13. [13] Andreasson, A.N., Unden, A.L., Elofsson, S., Brismar, K., Leptin and adiponectin: distribution and associations with cardiovascular risk factors in men and women of the general population. Am. J. Hum. Biol. 24:5 (2012), 595–601.
14. [14] Doehner, W., Pflaum, C.D., Rauchhaus, M., Godsland, I.F., Egerer, K., Cicoira, M., et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 145:6 (2001), 727–735.
15. [15] Karmazyn, M., Rajapurohitam, V., Leptin as a cardiac pro-hypertrophic factor and its potential role in the development of heart failure. Curr. Pharm. Des. 20:4 (2014), 646–651.
16. [16] Singhal, A., Farooqi, I.S., Cole, T.J., O'Rahilly, S., Fewtrell, M., Kattenhorn, M., et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?. Circulation 106:15 (2002), 1919–1924.
17. [17] Abd El-Aziz, T.A., Mohamed, R.H., Mohamed, R.H., Pasha, H.F., Leptin, leptin gene and leptin receptor gene polymorphism in heart failure with preserved ejection fraction. Heart Vessel. 27:3 (2012), 271–279.
18. [18] Puurunen, V.P., Lepojarvi, E.S., Piira, O.P., Hedberg, P., Junttila, M.J., Ukkola, O., et al. High plasma leptin levels are associated with impaired diastolic function in patients with coronary artery disease. Peptides, 2016.
19. [19] Fontes-Carvalho, R., Pimenta, J., Bettencourt, P., Leite-Moreira, A., Azevedo, A., Association between plasma leptin and adiponectin levels and diastolic function in the general population. Expert Opin. Ther. Targets, 2015, 1–9.
20. [20] Dong, M., Ren, J., What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Curr. Pharm. Des. 20:4 (2014), 652–658.
21. [21] Procopio, C., Andreozzi, F., Laratta, E., Cassese, A., Beguinot, F., Arturi, F., et al. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5′-monophosphate-activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology 150:8 (2009), 3584–3593.
22. [22] McEntegart, M.B., Awede, B., Petrie, M.C., Sattar, N., Dunn, F.G., MacFarlane, N.G., et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28:7 (2007), 829–835.
23. [23] Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112:12 (2005), 1756–1762.
24. [24] Tanaka, K., Wilson, R.M., Essick, E.E., Duffen, J.L., Scherer, P.E., Ouchi, N., et al. Effects of adiponectin on calcium handling proteins in heart failure with preserved ejection fraction. Circ. Heart Fail., 2014.
25. [25] O'Shea, K.M., Chess, D.J., Khairallah, R.J., Rastogi, S., Hecker, P.A., Sabbah, H.N., et al. Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am. J. Physiol. Heart Circ. Physiol. 298:6 (2010), H1639–H1645.
26. [26] Negi, S.I., Jeong, E.M., Shukrullah, I., Raicu, M., Dudley, S.C. Jr., Association of low plasma adiponectin with early diastolic dysfunction. Congest. Heart Fail. 18:4 (2012), 187–191.
27. [27] Fukuta, H., Ohte, N., Wakami, K., Goto, T., Tani, T., Kimura, G., Relation of plasma levels of adiponectin to left ventricular diastolic dysfunction in patients undergoing cardiac catheterization for coronary artery disease. Am. J. Cardiol. 108:8 (2011), 1081–1085.
28. [28] Sente, T., Van Berendoncks, A.M., Hoymans, V.Y., Vrints, C.J., Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J. Cachex. Sarcopenia Muscle 7:3 (2016), 261–274.
29. [29] Chen, C.Y., Asakura, M., Asanuma, H., Hasegawa, T., Tanaka, J., Toh, N., et al. Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertens. Res. 35:8 (2012), 843–848.
30. [30] George, J., Patal, S., Wexler, D., Sharabi, Y., Peleg, E., Kamari, Y., et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92:10 (2006), 1420–1424.
31. [31] Khan, R.S., Kato, T.S., Chokshi, A., Chew, M., Yu, S., Wu, C., et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ. Heart Fail. 5:3 (2012), 340–348.
32. [32] Tsukamoto, O., Fujita, M., Kato, M., Yamazaki, S., Asano, Y., Ogai, A., et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol. 53:22 (2009), 2070–2077.
33. [33] Antonopoulos, A.S., Margaritis, M., Coutinho, P., Digby, J., Patel, R., Psarros, C., et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 34:9 (2014), 2151–2159.
34. [34] Wang, Y., Gao, E., Lau, W.B., Wang, Y., Liu, G., Li, J.J., et al. G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. Circulation 131:16 (2015), 1392–1404.
35. [35] Ruan, H., Dong, L.Q., Adiponectin signaling and function in insulin target tissues. J. Mol. Cell Biol. 8:2 (2016), 101–109.
36. [36] Faxen, U.L., Hage, C., Benson, L., Zabarovskaja, S., Andreasson, A., Donal, E., et al. HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. J Card Fail, 2016.
37. [37] Fantuzzi, G., Adiponectin and inflammation: consensus and controversy. J. Allergy Clin. Imunol. 121:2 (2008), 326–330.
38. [38] Andreassen, A.N., Under, A.L., Elofson, S., Brismar, K., Leptin and adiponectin: distribution and associations with cardiovascular risk factors in men and women of the general population. AM. J. Hum. Bil. 24:5 (2012), 595–601.
39. [39] Person, J., Folkersen, L., Ekstrand, J., Helleberg, J., Gabrielsen, A., Lundman, P., et al. High plasma adiponectin concentration is associated with all-cause mortality in patients with carotid atherosclerosis. Atherosclerosis 225:2 (2012), 491–496.